These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 26033280

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.
    Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C.
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):937-47. PubMed ID: 20102746
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.
    Blood; 1998 Oct 01; 92(7):2303-14. PubMed ID: 9746768
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.
    Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA.
    Biol Blood Marrow Transplant; 2006 Dec 01; 12(12):1277-84. PubMed ID: 17162209
    [Abstract] [Full Text] [Related]

  • 28. CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation.
    Arranz R, Conde E, Rodriguez-Salvanés F, Pajuelo FJ, Cabrera R, Sanz MA, Petit J, Bueno J, Maldonado J, Odriozola J, Conde JG, Brunet S, Carreras E, Iriondo A, Fernández-Rañada JM, Marín P, Subcomité de Aplasia Medular del Grupo Español de Trasplante Hemopoyético.
    Bone Marrow Transplant; 2002 Feb 01; 29(3):205-11. PubMed ID: 11859392
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.
    Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A, Ayash L, Lum L, Waller EK, Ratanatharathorn V, Uberti J.
    Biol Blood Marrow Transplant; 2014 Jul 01; 20(7):979-85. PubMed ID: 24709007
    [Abstract] [Full Text] [Related]

  • 31. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
    Iguchi A, Terashita Y, Sugiyama M, Ohshima J, Sato TZ, Cho Y, Kobayashi R, Ariga T.
    Pediatr Transplant; 2016 Feb 01; 20(1):114-9. PubMed ID: 26526424
    [Abstract] [Full Text] [Related]

  • 32. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuk F, Erttmann R, Kabisch H, Zander AR.
    Ann Hematol; 2002 Nov 01; 81(11):627-31. PubMed ID: 12454700
    [Abstract] [Full Text] [Related]

  • 33. Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning.
    Iftikhar R, Chaudhry QUN, Mahmood SK, Ghafoor T, Satti HS, Shahbaz N, Khan MA, Khattak TA, Shamshad GU, Rehman J, Farhan M, Humayun S, Risalat A, Wahab A, Satti TM, Anwer F, Ahmed P.
    Biol Blood Marrow Transplant; 2020 Dec 01; 26(12):2245-2251. PubMed ID: 32717437
    [Abstract] [Full Text] [Related]

  • 34. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
    Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS.
    J Clin Oncol; 2021 Jun 10; 39(17):1865-1877. PubMed ID: 33449816
    [Abstract] [Full Text] [Related]

  • 35. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
    Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K.
    Blood; 1992 Oct 01; 80(7):1838-45. PubMed ID: 1391947
    [Abstract] [Full Text] [Related]

  • 36. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
    Chen X, Wei JL, Huang Y, He Y, Yang DL, Jiang EL, Ma QL, Zhou LK, Lin XT, Shen YY, Feng SZ, Han MZ.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug 01; 33(8):610-4. PubMed ID: 23134851
    [Abstract] [Full Text] [Related]

  • 37. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
    Carnevale-Schianca F, Leisenring W, Martin PJ, Furlong T, Schoch G, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem HP, Storb R, McDonald GB, Nash RA.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):749-56. PubMed ID: 19450760
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
    Maury S, Balère-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K, Bordigoni P, Marie-Cardine A, Milpied N, Kanold J, Maillard N, Socié G, French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
    Haematologica; 2007 May 01; 92(5):589-96. PubMed ID: 17488681
    [Abstract] [Full Text] [Related]

  • 40. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
    Soltermann Y, Heim D, Medinger M, Baldomero H, Halter JP, Gerull S, Arranto C, Passweg JR, Kleber M.
    Ann Hematol; 2019 Jun 01; 98(6):1485-1493. PubMed ID: 30915500
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.